Hematologic changes during prostate cancer radiation therapy are dependent on the treatment volume

Future Oncology

Volumn 10, Issue 5, 2014, Pages 835-843

  Pinkawa, Michael ^a   Djukic, Victoria ^a   Klotz, Jens ^a   Petz, Dalma ^a   Piroth, Marc D ^a   Holy, Richard ^a   Eble, Michael J ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

hematologic toxicity; intensity modulated radiation therapy; postoperative radiation therapy; prostate cancer

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; HEMOGLOBIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANEMIA; ANTIANDROGEN THERAPY; ARTICLE; BLOOD SAMPLING; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; EOSINOPHIL COUNT; ERYTHROCYTE COUNT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LEUKOCYTE DIFFERENTIAL COUNT; LEUKOPENIA; LINEAR ACCELERATOR; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTILEAF COLLIMATOR; NEUTROPHIL COUNT; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; SALVAGE THERAPY; THROMBOCYTE COUNT; ADJUVANT THERAPY; BLOOD; BLOOD CELL COUNT; ERYTHROCYTE; LYMPHOCYTE; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROSTATIC NEOPLASMS; RADIATION RESPONSE; THROMBOCYTE;

BLOOD CELL COUNT; BLOOD PLATELETS; COMBINED MODALITY THERAPY; ERYTHROCYTES; HEMOGLOBINS; HUMANS; LYMPHOCYTES; MALE; NEOADJUVANT THERAPY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84899882406     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.237     Document Type: Article

References (33)

1. Center MM, Jemal A, Lortet-Tieulent J et al. International variation in prostate cancer incidence and mortality rates. Eur. Urol. 61, 1079-1092 (2012).
2. Heidenreich A, Bellmunt J, Bolla M et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur. Urol. 59, 61-71 (2011).
3. Peinemann F, Grouven U, Bartel C et al. Permanent interstitial low-dose-rate brachytherapy for patients with localised prostate cancer: a systematic review of randomised and nonrandomised controlled clinical trials. Eur. Urol. 60, 881-893 (2011).
4. Thompson IM, Tangen CM, Paradelo J et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J. Urol. 181, 956-962 (2009).
5. Wiegel T, Bottke D, Steiner U et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J. Clin. Oncol. 27, 2924-2930 (2009).
6. Bolla M, van Poppel H, Tombal B et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 380, 2018-2027 (2012).
7. McBride WH, Withers HR. Biological basis of radiation therapy. In: Princliples and Practice of Radiation Oncology. Halperin CW, Wazer DE, Perez CA, Brady LW (Eds). Lippincott Williams &Wilkins, PA, USA, 61-88 (2013).
8. Zelefsky MJ, Housman DM, Pei X et al. Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 83, 953-959 (2012).
9. Patil VM, Kapoor R, Chakraborty S et al. Dosimetric risk estimates of radiation-induced malignancies after intensity modulated radiotherapy. J. Cancer Res. Ther. 6, 442-447 (2010).
10. Pinkawa M, Schoth F, Bohmer D et al. Current standards and future directions for prostate cancer radiation therapy. Expert Rev. Anticancer Ther. 13, 75-88 (2013).
11. Morikawa LK, Roach M III. Pelvic nodal radiotherapy in patients with unfavorable intermediate and high-risk prostate cancer: evidence, rationale, and future directions. Int. J. Radiat. Oncol. Biol. Phys. 80, 6-16 (2011).
12. Cozzarini C, Bolognesi A, Ceresoli GL et al. Role of postoperative radiotherapy after pelvic lymphadenectomy and radical retropubic prostatectomy: a single institute experience of 415 patients. Int. J. Radiat. Oncol. Biol. Phys. 59, 674-683 (2004).
13. Roach M III, DeSilvio M, Valicenti R et al. Whole-pelvis, 'mini-pelvis,' or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int. J. Radiat. Oncol. Biol. Phys. 66, 647-653 (2006).
14. Pommier P, Chabaud S, Lagrange JL et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J. Clin. Oncol. 25, 5366-5373 (2007).
15. Pinkawa M, Piroth MD, Holy R et al. Quality of life after whole pelvic versus prostate-only external beam radiotherapy for prostate cancer: a matched-pair comparison. Int. J. Radiat. Oncol. Biol. Phys. 81, 23-28 (2011).
16. Carles J, Nogue M, Sole JM et al. Phase II study of vinorelbine and estramustine in combination with conformational radiotherapy for patients with high-risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 76, 1085-1091 (2010).
17. Finkelstein SE, Fishman M. Clinical opportunities in combining immunotherapy with radiation therapy. Front. Oncol. 2, 169 (2012).
18. Hussain A, Wu Y, Mirmiran A et al. Long-term follow-up of a prospective trial of trimodality therapy of weekly paclitaxel, radiation, and androgen deprivation in high-risk prostate cancer with or without prior prostatectomy. Int. J. Radiat. Oncol. Biol. Phys. 82, 167-174 (2012).
19. Vuky J, Pham HT, Warren S et al. Phase II study of long-term androgen suppression with bevacizumab and intensity-modulated radiation therapy (IMRT) in high-risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 82, e609-e615 (2012).
20. Finkelstein SE, Rodriguez F, Dunn M et al. Serial assessment of lymphocytes and apoptosis in the prostate during coordinated intraprostatic dendritic cell injection and radiotherapy. Immunotherapy 4, 373-382 (2012).
21. Finkelstein SE, Iclozan C, Bui MM et al. Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients. Int. J. Radiat. Oncol. Biol. Phys. 82, 924-932 (2012).
22. Blank KR, Cascardi MA, Kao GD. The utility of serial complete blood count monitoring in patients receiving radiation therapy for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 44, 317-321 (1999).
23. Zachariah B, Jacob SS, Gwede C et al. Effect of fractionated regional external beam radiotherapy on peripheral blood cell count. Int. J. Radiat. Oncol. Biol. Phys. 50, 465-472 (2001).
24. Pinkawa M, Attieh C, Piroth MD et al. Dose-escalation using intensity-modulated radiotherapy for prostate cancer-evaluation of the dose distribution with and without 18F-choline PET-CT detected simultaneous integrated boost. Radiother. Oncol. 93, 213-219 (2009).
25. Pinkawa M, Holy R, Piroth DM et al. Intensity-modulated radiotherapy for prostate cancer implementing molecular imaging with 18F-choline PET-CT to define a simultaneous integrated boost. Strahlenther. Onkol. 186, 600-606 (2011).
26. Pinkawa M, Eble MJ, Mottaghy FM. PET and PET/CT in radiation treatment planning for prostate cancer. Expert Rev. Anticancer Ther. 11, 1033-1039 (2011).
27. Pinkawa M, Pursch-Lee M, Asadpour B et al. Image-guided radiotherapy for prostate cancer. Implementation of ultrasound-based prostate localization for the analysis of inter- and intrafraction organ motion. Strahlenther. Onkol. 184, 679-685 (2008).
28. Lawton CA, DeSilvio M, Roach M, III et al. An update of the Phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int. J. Radiat. Oncol. Biol. Phys. 69, 646-655 (2007).
29. Ellis RE. The distribution of active bone marrow in the adult. Phys. Med. Biol. 5, 255-258 (1961).
30. Hall EJ, Giaccia AJ. Clinical response of normal tissue. In: Radiobiology for the Radiologist. Hall EJ, Giaccia AJ (Eds). Lippincott Williams &Wilkins, PA, USA, 327-348 (2006).
31. Krook JE, Moertel CG, Gunderson LL et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N. Engl. J. Med. 324, 709-715 (1991).
32. Keys HM, Bundy BN, Stehman FB et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N. Engl. J. Med. 340, 1154-1161 (1999).
33. Lester-Coll NH, Goldhaber SZ, Sher DJ, D'Amico AV. Death from high-risk prostate cancer versus cardiovascular mortality with hormonal therapy: a decision analysis. Cancer 119, 1808-1815 (2013).